Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

National Healthcare (NHC) Cash from Financing Activities (2016 - 2025)

National Healthcare (NHC) has disclosed Cash from Financing Activities for 16 consecutive years, with -$43.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 123.98% year-over-year to -$43.2 million, compared with a TTM value of -$136.0 million through Dec 2025, down 235.49%, and an annual FY2025 reading of -$136.0 million, down 235.49% over the prior year.
  • Cash from Financing Activities was -$43.2 million for Q4 2025 at National Healthcare, up from -$47.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $139.3 million in Q3 2024 and bottomed at -$47.0 million in Q3 2025.
  • Average Cash from Financing Activities over 5 years is -$8.1 million, with a median of -$10.4 million recorded in 2022.
  • The sharpest move saw Cash from Financing Activities skyrocketed 1518.74% in 2024, then crashed 333.98% in 2025.
  • Year by year, Cash from Financing Activities stood at -$9.5 million in 2021, then fell by 27.45% to -$12.1 million in 2022, then increased by 18.73% to -$9.8 million in 2023, then tumbled by 96.22% to -$19.3 million in 2024, then tumbled by 123.98% to -$43.2 million in 2025.
  • Business Quant data shows Cash from Financing Activities for NHC at -$43.2 million in Q4 2025, -$47.0 million in Q3 2025, and -$33.0 million in Q2 2025.